ZEALAND PHARMA A S's ticker is ZEAL and the CUSIP is 98920Y304. A total of 12 filers reported holding ZEALAND PHARMA A S in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $312,000 | -15.4% | 23,976 | +1.1% | 0.00% | – |
Q1 2022 | $369,000 | -29.3% | 23,714 | -3.0% | 0.00% | – |
Q4 2021 | $522,000 | +76.9% | 24,441 | +143.6% | 0.00% | – |
Q3 2021 | $295,000 | -68.8% | 10,032 | -68.9% | 0.00% | – |
Q2 2021 | $946,000 | -27.1% | 32,210 | -20.6% | 0.00% | -100.0% |
Q1 2021 | $1,297,000 | +1.1% | 40,590 | +13.7% | 0.00% | 0.0% |
Q4 2020 | $1,283,000 | +26.8% | 35,707 | +35.5% | 0.00% | 0.0% |
Q3 2020 | $1,012,000 | -20.4% | 26,355 | -27.5% | 0.00% | 0.0% |
Q2 2020 | $1,272,000 | +121.2% | 36,331 | +118.1% | 0.00% | 0.0% |
Q1 2020 | $575,000 | +19.3% | 16,656 | +22.2% | 0.00% | 0.0% |
Q4 2019 | $482,000 | +58.6% | 13,634 | +14.2% | 0.00% | 0.0% |
Q3 2019 | $304,000 | -5.0% | 11,942 | -52.8% | 0.00% | 0.0% |
Q4 2018 | $320,000 | +92.8% | 25,285 | +134.2% | 0.00% | – |
Q1 2018 | $166,000 | -34.6% | 10,798 | -41.8% | 0.00% | -100.0% |
Q4 2017 | $254,000 | -34.2% | 18,558 | -7.2% | 0.00% | 0.0% |
Q3 2017 | $386,000 | – | 19,999 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
FARALLON CAPITAL MANAGEMENT LLC | 500,000 | $17,500,000 | 0.14% |
AWM Investment Company, Inc. | 19,981 | $699,000 | 0.12% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 5,653 | $187,000 | 0.06% |
WELLINGTON MANAGEMENT GROUP LLP | 1,103,980 | $38,640,000 | 0.01% |
ROYCE & ASSOCIATES LP | 10,000 | $350,000 | 0.00% |
Winslow, Evans & Crocker, Inc. | 235 | $8,000 | 0.00% |
Rockefeller Capital Management L.P. | 4,994 | $175,000 | 0.00% |
JANE STREET GROUP, LLC | 36,331 | $1,272,000 | 0.00% |
Renaissance Technologies | 26,000 | $910,000 | 0.00% |
US BANCORP \DE\ | 260 | $9,000 | 0.00% |